Search

Displaying results 2061 - 2070 of 8517 in total
  1. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer.

  2. Drug

    Methane

    go.drugbank.com/drugs/DB15994
    Investigational

    Mixtures: iCOmas 0,3 % / 0,3 % / 0,3 % Gas zur medizinischen Anwendung, druckverdichtet
  3. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Ombutasvir first came on the market as a fixed-dose combination product with [DB09183], [DB09297], and [DB00503] as the FDA-approved product Viekira Pak.

    Synonyms: dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
  4. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP

  5. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  6. Drug

    Phthalylsulfathiazole

    go.drugbank.com/drugs/DB13248
    Approved

    It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

  7. Drug

    Kaolin

    go.drugbank.com/drugs/DB01575
    Approved

    Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. … Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate.

  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    of a peptidase-resistant formulation has allowed for its use as a viable treatment option in achondroplasia. … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development

  9. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

  10. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion. … The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.